 NEW YORK, July 28, 2020 GLOBE NEWSWIRE -- PAVmed Inc. Nasdaq: PAVM, PAVMZ the Company or PAVmed, a highly differentiated, multi-product, commercial-stage medical device company, today announced that the Company will host a business update conference call on Tuesday, August 18, 2020 at 4:30 p.m. Eastern time. During the call, Lishan Aklog, M.D., Chairman and Chief Executive Officer of the Company, will provide a business update including an overview of the Companys near-term milestones and growth strategy. In addition, Dennis McGrath, the Companys President and Chief Financial Officer, will discuss second quarter 2020 financial results. To access the conference call, U.S.-based listeners should dial 877 407-3982 and international listeners should dial 201 493-6780. All listeners should provide the operator with the conference call name PAVmed, Inc. Business Update Conference Call to join. Individuals interested in listening to the live conference call via webcast may do so by visiting the investor relations section of the Companys website at the conclusion of the conference call, a replay will be available for one week and can be accessed by dialing 844 512-2921 from within the U.S. or 412 317-6671 from outside the U.S. To access the replay, all listeners should provide the following pin number: 13707223. The webcast will be available for replay on the investor relations section of the Companys website at PAVmedPAVmed Inc. is a highly differentiated, multi-product, commercial-stage medical device company employing a unique business model designed to advance innovative products to commercialization rapidly and with less capital than the typical medical device company. This proprietary model enables PAVmed to pursue an expanding pipeline strategy with a view to enhancing and accelerating value creation while seeking to further expand its pipeline through relationships with its network of clinician innovators at leading academic centers. PAVmeds diversified product pipeline addresses unmet clinical needs encompassing a broad spectrum of clinical areas with attractive regulatory pathways and market opportunities. Its four operating divisions include GI Health EsoGuardTM Esophageal DNA Test, EsoCheckTM Esophageal Cell Collection Device, and EsoCureTM Esophageal Ablation Device with CaldusTM Technology, Minimally Invasive Interventions CarpXTM Minimally Invasive Device for Carpal Tunnel Syndrome, Infusion Therapy PortIOTM Implantable Intraosseus Vascular Access Device and NextFloTM Highly Accurate Disposable Intravenous Infusion Set, and Emerging Innovations non-invasive laser-based glucose monitoring, pediatric ear tubes, and mechanical circulatory support. For more information, please visit follow us on Twitter, connect with us on LinkedIn, and watch our videos on YouTube. For more information on our majority owned subsidiary, Lucid Diagnostics Inc., please visit follow Lucid on Twitter, and connect with Lucid on LinkedIn.Forward-Looking StatementsThis press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements, based upon the current beliefs and expectations of PAVmeds management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of PAVmeds common stock, Series W Warrants and Series Z Warrants; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required advance PAVmeds products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmeds preclinical studies; whether and when PAVmeds products are cleared by regulatory authorities; market acceptance of PAVmeds products once cleared and commercialized; our ability to raise additional funding and other competitive developments. PAVmed has not yet received clearance from the FDA or other regulatory body to market many of its products. The Company has been monitoring the COVID-19 pandemic and its impact on our business. The Company expects the significance of the COVID-19 pandemic, including the extent of its effect on the Companys financial and operational results, to be dictated by, among other things, the success of efforts to contain it and the impact of actions taken in response. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond PAVmeds control. For a further list and description of these and other important risks and uncertainties that may affect PAVmeds future operations, see Part I, Item IA, Risk Factors, in PAVmeds most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, Risk Factors in any Quarterly Reports on Form 10-Q filed by PAVmed after its most recent Annual Report. PAVmed disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.Contacts:Investors Mike Havrilla Director of Investor Relations 814 241-4138 Shaun ONeil Chief Commercial Officer 518 812-3087 